Halozyme Therapeutics (HALO) Amortization - Intangibles (2022 - 2026)

Halozyme Therapeutics (HALO) has 5 years of Amortization - Intangibles data on file, last reported at $29.5 million in Q1 2026.

• On a quarterly basis, Amortization - Intangibles rose 66.15% year-over-year to $29.5 million in Q1 2026; TTM through Mar 2026 was $88.4 million, a 24.44% increase from a year earlier, with the FY2025 full-year figure at $76.7 million, up 7.9% from the prior year.
• Amortization - Intangibles for Q1 2026 stood at $29.5 million, up from $23.4 million in the prior quarter.
• Over the last five years, Amortization - Intangibles for HALO reached as high as $29.5 million in Q1 2026 and fell as low as $4.6 million in Q4 2022.
• Historically, Amortization - Intangibles has averaged $18.4 million across 5 years, with a median of $17.8 million in 2023.
• On a YoY basis, Amortization - Intangibles climbed as much as 290.2% in 2023 and fell as far as 25.2% in 2023.
• Year by year, Amortization - Intangibles stood at $4.6 million in 2022, then surged by 290.2% to $17.8 million in 2023, then changed by 0.0% to $17.8 million in 2024, then soared by 31.61% to $23.4 million in 2025, then rose by 26.25% to $29.5 million in 2026.
• Per Business Quant data, the three most recent Amortization - Intangibles figures were $29.5 million in Q1 2026, $23.4 million in Q4 2025, and $17.8 million in Q3 2025.